Tuesday, August 23, 2011

Vivus to raise $45M in stock sale

Drug developer Vivus made a deal with institutional investors, who agreed to buy 6.889 million shares at $6.65 per share. The company will net a little more than $45 million after expenses of about $562,000.

No comments:

Post a Comment